Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75

Benzinga Newsdesk www.benzinga.com Negative 89.9%

Neg 89.9% Neu 0% Pos 0%

Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $5.5 to $4.75.